These compounds graduated from The Orchard. Available by prescription now.
The same semaglutide molecule — no needle. FDA approved December 22, 2025 as the first oral GLP-1 receptor agonist approved specifically for weight management in the US. Launched in January 2026. The OASIS 4 Phase 3 trial showed 16.6% mean weight loss — comparable to injectable Wegovy — with 1 in 3 participants losing 20% or more of body weight. Also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease.
Important practical note: the Wegovy pill requires an empty stomach, no more than 120ml of water, and a 30-minute fast afterward. That's the main limitation versus the second oral option below. The access implication is still real — removing the injection barrier changes who starts treatment and who sticks with it.
The second oral GLP-1 to reach approval — and the one that solves the problem the Wegovy pill didn't. Foundayo can be taken any time of day, with or without food, with no water restrictions. That's a meaningful clinical distinction. The Wegovy pill requires an empty stomach and a 30-minute wait. Foundayo doesn't. That difference matters for adherence.
It's also a fundamentally different class of molecule — a small-molecule (non-peptide) GLP-1 receptor agonist rather than a peptide analog. FDA approved April 1, 2026 under the accelerated Commissioner's National Priority Voucher program — the fastest approval of a new molecular entity since 2002. The ATTAIN-1 Phase 3 trial across 3,127 adults showed 11.2% average weight loss at approved doses over 72 weeks, with 54.6% of participants losing at least 10% of starting body weight. Weight loss is somewhat less than injectable tirzepatide or retatrutide — but the convenience and access profile are genuinely different. Originally discovered by Chugai Pharmaceutical, developed by Eli Lilly.
NDA filed or Phase 3 complete. These are the compounds your doctor may be following right now.
The most directly relevant pipeline compound for people currently on semaglutide. CagriSema combines semaglutide with cagrilintide — a long-acting amylin analog that targets satiety pathways GLP-1 doesn't reach. Amylin and GLP-1 work through different receptors in the brain's satiety centers. Combining them produces results neither achieves alone.
The REDEFINE 1 Phase 3 trial across 3,417 adults showed 22.7% average weight loss vs. 16.1% with semaglutide alone. More than half of participants lost 20%+. 88% of pre-diabetic participants returned to normal blood glucose. NDA filed December 18, 2025. FDA decision expected approximately October 2026 based on standard 10-month review.
One important nuance: the REDEFINE 4 head-to-head trial versus tirzepatide 15mg over 84 weeks showed CagriSema achieved 23% weight loss — strong — but did not meet the primary endpoint of non-inferiority against tirzepatide. That's a clinically honest result. The absolute numbers are impressive; it just didn't beat Zepbound in a direct comparison at those doses.
The body composition problem with GLP-1 therapy is real: 25–40% of weight lost typically comes from lean mass, not fat. Pemvidutide is specifically trying to change that ratio. In the Phase 2 MOMENTUM trial, pemvidutide produced 10.3% body weight loss at 48 weeks — but only 21.9% of the weight lost was lean mass. That's the best lean-mass-preservation ratio documented in any GLP-1 class trial to date.
The glucagon receptor component appears to activate metabolic pathways that preferentially target fat while protecting muscle. Phase 3 has not yet been initiated. If you're losing significant weight on a GLP-1 medication and concerned about muscle loss — and you should be — this is the compound to follow as it develops.
The most remarkable body composition result published in the GLP-1 research space. The BELIEVE Phase 2b trial combined bimagrumab — an antibody that blocks myostatin, the protein that limits muscle growth — with semaglutide 2.4mg. The result: 22.1% total weight loss with 92.8% coming from fat mass, versus semaglutide alone at 71.8% fat. Some participants actually gained lean mass while losing significant body weight simultaneously.
Published in JAMA 2025. No Phase 3 timeline announced. This combination doesn't exist as an approved treatment — and may be years from one — but the data is among the most compelling in metabolic medicine for anyone for whom body composition, not just weight, is the goal.
Three receptors. One molecule. Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously — unlocking fat-burning mechanisms in the liver and bloodstream that earlier compounds don't reach. Phase 3 TRIUMPH-4 results (68 weeks, 12mg dose): 32.3kg / 71 lbs average weight loss — the highest ever recorded in a pharmacological trial. Beyond the scale: 75.8% reduction in WOMAC knee pain scores, with 1 in 8 participants completely pain-free at 68 weeks. Approaching bariatric surgery outcomes with a mechanism that also heals joints. As of May 2026, Eli Lilly has not yet filed an NDA with the FDA.
As of April 2026, Eli Lilly has not yet filed an NDA with the FDA. Filing is anticipated but no date has been confirmed. Also available as a research use only compound — an area of active personal research at BritePear.
Real science. Real direction. Years from the prescription pad. Watch this space.
To understand why this matters, follow the progression of the field:
Each generation has meaningfully outperformed the last. Early animal data reportedly outperforms retatrutide — which has been treated as the current ceiling. The research is funded by Eli Lilly and based at the Indiana Biosciences Research Institute. Animal data is set to be presented at the ADA Scientific Sessions on May 29, 2026. "2839-LB" circulating in the peptide research community is the ADA presentation slot number — not a drug name or compound identifier.
The first four receptors target appetite and fat burning. Calcitonin is different. Rapid weight loss on tirzepatide and retatrutide causes measurable bone density loss — a known but underreported side effect of the class. Calcitonin's classical function is bone protection. A calcitonin component in a weight loss compound could theoretically offset that bone loss — which would be a first in this class. Early research also points to cartilage-protective and anti-inflammatory effects, directly relevant to the joint health story retatrutide's knee osteoarthritis data has already opened up.
No official Lilly press release. No named compound. No pipeline entry. The concept is scientifically legitimate — a separate quintuple agonist from Helmholtz Zentrum München targeting GLP-1 + GIP + three PPAR receptors was presented at EASD 2025, proving the multi-receptor approach is real science. Mouse-to-market historically takes 8–12 years. Retatrutide isn't approved yet. The quintuple, if it clears human trials, is a story for the early 2030s at the earliest.